Stefan Svensson Gelius

Title: Innovations by Stefan Svensson Gelius

Introduction

Stefan Svensson Gelius is a notable inventor based in Älvsjö, Sweden. He has made significant contributions to the field of biotechnology, particularly in the development of fusion proteins and modified enzymes. With a total of two patents to his name, his work has the potential to impact therapeutic applications significantly.

Latest Patents

One of his latest patents is for a fusion protein that includes a biologically active polypeptide and a half-life extending polypeptide moiety. This innovative fusion protein is designed to have a generally unfolded conformation, which increases its hydrodynamic radius and helps avoid renal clearance. As a result, the biological half-life of the fusion protein is extended, thereby prolonging the biological effect of the active polypeptide. Another significant patent involves a modified sulfamidase, which is designed to cross the blood-brain barrier effectively. This modified enzyme has substantially no epitopes for glycan recognition receptors, allowing it to maintain catalytic activity in the brain, which could have therapeutic implications for various neurological conditions.

Career Highlights

Stefan Svensson Gelius is currently employed at Swedish Orphan Biovitrum AB (publ), a company known for its focus on developing treatments for rare diseases. His work at the company has allowed him to collaborate with other talented professionals in the field, contributing to advancements in biopharmaceuticals.

Collaborations

Some of his notable coworkers include Erik Nordling and Charlotta Berghard. Their collaborative efforts have likely played a role in the successful development of innovative therapeutic solutions.

Conclusion

Stefan Svensson Gelius is a prominent inventor whose work in biotechnology has led to significant advancements in therapeutic applications. His patents reflect a commitment to improving medical treatments and enhancing the quality of life for patients.